One hundred cases of severe paracetamol poisoning were treated with intravenous N-acetylcysteine (acetylcysteine). There was virtually complete protection against liver damage in 40 patients treated within eight hours after ingestion (mean maximum serum alanine transaminase activity 27 IU/1). Only one out of 62 patients treated within 10 hours developed severe liver damage compared with 33 out of 57 patients (58%) studied retrospectively who received supportive treatment alone. Early treatment with acetylcysteine also prevented renal impairment and death. The critical ingestiontreatment interval for complete protection against severe liver damage was eight hours. Efficacy diminished progressively thereafter, and treatment after 15 hours was completely ineffective.
Introduction
Now that the biochemical mechanisms of paracetamol hepatotoxicity are understood' sulphydryl compounds such as cysteamine, L-methionine, and N-acetylcysteine (acetylcysteine) may be used successfully to treat severe paracetamol poisoning.2-10 Nevertheless, the relative efficacy of these agents in protecting against liver damage, renal impairment, and death is uncertain and doubts have been raised about the safety of cysteamine and methionine.2-8 Furthermore, cysteamine and methionine are not available commercially for intravenous administration. Our initial findings with intravenous acetylcysteine were encouraging,4 5 and we describe here the results of treating 100 cases.
Patients and methods
Patients-Eighty-seven patients admitted on 100 occasions with severe paracetamol poisoning between December 1976 and May 1979 were treated with intravenous acetylcysteine. Their mean age was 33 years (range , and 33 were male. Those admitted on more than one occasion were considered as separate patients for each admission. Forty-eight patients claimed to have taken only paracetamol, 31 took it in combination with dextropropoxyphene as Distalgesic, and the remainder also took one or more other drugs, usually benzodiazepines or aspirin. All patients were admitted within 24 hours after ingestion and had plasma paracetamol concentrations above a treatment line joining plots of 200 mg/l at four hours and 30 mg/l at 15 hours on a semilogarithmic graph. More-severely poisoned patients with plasma paracetamol concentrations above a similar line joining 300 mg/l at four hours and 45 mg/l at 15 hours were defined as "high-risk" cases. Patients with values between these two lines were designated as an "intermediate-risk" group. When necessary the lines were extrapolated to 24 hours.
General management-Gastric aspiration and lavage were performed on patients admitted within four hours of ingestion and those in coma. Patients with persistent nausea and vomiting were given intravenous fluid replacement and antiemetics. Impending or established hepatic failure was treated conventionally. Twenty-one patients who took Distalgesic required naloxone-20 were in deep coma, and respiratory arrest had occurred in 10. Treatment with acetylcysteine-Intravenous acetylcysteine was given in an initial dose of 150 mg/kg in 200 ml 5% dextrose over 15 minutes followed by 50 mg/kg in 500 ml 5% dextrose over four hours and 100 mg/kg in one litre 5% dextrose over the next 16 hours (total dose 300 mg/kg in 20 hours). Roughly half of the patients were given Airbron, which is a 20% sterile aqueous solution of acetylcysteine for intrabronchial use. The remainder were given a similar solution specially prepared by the manufacturer for intravenous use.
Investigations-Initially, the pulse rate, blood pressure, temperature, and electrocardiogram (ECG) were monitored closely during administration of acetylcysteine. Full blood counts and estimations of prothrombin-time ratio, activities of serum aspartate transaminase (SGOT; serum AST) and serum alanine transaminase (SGPT; serum ALT), and plasma bilirubin, urea, creatinine, and electrolyte concentrations were usually performed on admission and daily for three to five days. Plasma paracetamol concentrations measured on admission1" were confirmed by specific chromatographic methods.12 13 Assessment of acetylcysteine-The efficacy of acetylcysteine was assessed by comparing it with the results of supportive treatment given alone to 57 similarly poisoned patients. Most of these had been admitted during 1969-73, before specific treatment became available. Comparisons were also made with 40 patients treated with intravenous cysteamine and 20 treated with intravenous methionine during 1973-6.3 All had plasma paracetamol concentrations above the treatment line, and except for the use of specific treatment their management was similar to that in the acetylcysteine-treated group. Severe liver damage was defined as an increase in serum AST or ALT activity above 1000 IU/i and renal impairment as a rise in the plasma creatinine concentration from normal to over 300 umol/l (3 4 mg/100 ml).
Results
Patients given supportive treatment, acetylcysteine, and cysteamine and methionine were broadly comparable in age, sex, severity of poisoning, and ingestion-admission interval (table I). More patients treated with acetylcysteine, however, had taken paracetamol with other drugs and alcohol, and there was a highly significant excess of Distalgesic poisoning in this group compared with the group given supportive treatment (x2= 14 9; P < 0 001).
LIVER DAMAGE
Acetylcysteine given within 10 hours-Only one of the 62 patients given acetylcysteine within 10 hours developed severe liver damage compared with 33 (58%) of the 57 patients given supportive treatment. Severe liver damage occurred in one of the 62 patients given acetylcysteine, none of the 27 given cysteamine, and three of the 15 given methionine, the mean maximum serum ALT activities in the three groups being 113, 149, and 1415 IU/l respectively. Serum ALT activity remained normal in 47 (76%) of the patients given acetylcysteine compared with 11 (41%) and six (40%) of those given cysteamine and methionine respectively (X2 = 8-7 and 5-6; P <001 and <0 02). Of the high-risk patients treated within eight hours, 19 given acetylcysteine had a mean serum ALT activity of 30 IU/i compared with 222 IU/l in 12 given cysteamine and methionine (t=2297; P<0 01). Hence acetylcysteine was apparently more effective than cysteamine and methionine. The critical ingestiontreatment interval appeared to be the same for all three compounds. The incidences of severe liver damage, fatal hepatic failure, and renal impairment were similar with supportive treatment and cysteamine, methionine, and acetylcysteine given 10-24 hours after ingestion.
SAFETY OF ACETYLCYSTEINE
Acetylcysteine did not produce any obvious side effects. Unlike cysteamine it did not cause protracted vomiting, drowsiness, irritability, and malaise. Hypokalaemia and low plasma bicarbonate concentrations were often noted during the first 72 hours, and there was a tendency towards low platelet counts, especially in patients with severe liver damage. Acetylcysteine was not responsible, however, since similar changes were observed with cysteamine, methionine, and supportive treatment. Serial ECGs often showed transient generalised T-wave flattening and prominent U waves consistent with hypokalaemia.
Discussion
Intravenous acetylcysteine was clearly highly effective in protecting against severe liver damage, renal failure, and death after paracetamol overdosage when given within 8-10 hours of ingestion. As with cysteamine and methionine, the incidence and severity of liver damage rose as the interval between ingestion and treatment increased beyond eight hours, and treatment after 15 hours was ineffective. The importance of the critical ingestion-treatment interval is sometimes not appreciated, and conflicting claims have been made. Douglas et al'4 believed that cysteamine was of no definite advantage whether given before or after nine hours, while Smith et a18 concluded that it might prevent further liver damage when given up to 72 hours after ingestion of paracetamol.
Our use of patients given supportive treatment as historical controls was not ideal, but to withhold specific treatment in clinical trials would be unethical. Our results suggest that in the doses used acetylcysteine is more effective than cysteamine and methionine. Methionine seemed to be the least effective. Despite administration within 10 hours, severe liver damage occurred in 200% of our patients and in 4-100%" of patients given oral methionine in other studies.7 15 Oral acetylcysteine has been used for paracetamol poisoning in the USA, Vancouver style All manuscripts submitted to the BMJ from now on should conform to the uniform requirements for manuscripts submitted to biomedical journals (known as the Vancouver style).
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